| 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease | An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkinson's Disease – INSIGHTS Study - INSIGHTS Study | EUCTR2014-004865-26-DE |
| Effect of L-dopa In Subacute Back Pain Population | Corticostriatal Plasticity in the Transition to Chronic Pain: Effect of L-dopa | NCT01951105 |
| Pharmacokinetics of IPX203 | IPX203-B13-02:Pharmacokinetics of IPX203 and Levodopa formulations in healthy volunteers | ACTRN12613001057774 |
| Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral Administration | Open-label, Two-treatment, 4-period Replicated Crossover Study in Healthy Subjects to Investigate the Plasma Pharmacokinetics of Levodopa and Carbidopa After Oral Administration of Single Doses of Two Fixed-dose Combination Products | NCT02116465 |
| Differential susceptibility to L-Dopa in caregiving | DRD4 genotype as a moderator of L-Dopa intervention effects on parent-related neurocognitive processes, behaviors, and attitudes: A micro-trial of differential susceptibility to pharmacological intervention - Differential susceptibility to L-Dopa in caregiving | EUCTR2014-000206-36-NL |
| The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics | The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics When Administered With Immediate-release 100/25 mg Levodopa/Carbidopa in Healthy Subjects | NCT02170376 |
| EFFECT OF SEROTONIN AND LEVODOPA FUNCTIONAL RECOVERY IN PATIENTS WITH CEREBRAL INFARCTION | EFFECT OF SEROTONIN AND LEVODOPA FUNCTIONAL RECOVERY IN PATIENTS WITH CEREBRAL INFARCTION - SELEIS | EUCTR2014-000846-32-ES |
| Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa | """Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa""; ""Inflammation Effects on Corticostriatal Connectivity and Reward: Role of Dopamine""" | NCT02513485 |
| Registry for Apomorphine-, L-Dopa-Infusiontherapy and Deep Brain Stimulation in Patients with Parkinson’s Disease | Registry for Apomorphine-, L-Dopa-Infusiontherapy and Deep Brain Stimulation in Patients with Parkinson’s Disease - Real-DBS-PD | DRKS00006735 |
| The INVEST study Treatment in advanced Parkinson’s disease: continuous intrajejunal levodopa INfusion VErsus deep brain STimulation. | The INVEST study Treatment in advanced Parkinson’s disease: continuous intrajejunal levodopa INfusion VErsus deep brain STimulation. | NL-OMON21505 |
| A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease | A Phase 3, Randomized Study Investigating the Safety ofCVT-301 (Levodopa Inhalation Powder) in Parkinson’s DiseasePatients With Motor Response Fluctuations (OFF Phenomena)Compared to an Observational Cohort Control | EUCTR2014-003799-22-HU |
| A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) | A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Doses Administered Using a Divided Dose Approach | NCT02486432 |
| Pharmacokinetic Study in Healthy Males | Pharmacokinetics of Levodopa, Carbidopa, 3-OMD and ODM-104 After Repeated Doses of Different Formulations: an Open, Randomised, Multicentre Study With Crossover Design in Healthy Males | NCT02312232 |
| Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation | The Effect of Combining Robotic-Assisted Therapy With Levodopa/Carbidopa in Chronic Post-Stroke Upper-Limb Hemiparesis | NCT02346630 |
| Pharmacokinetic Study in Healthy Volunteers | Pharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Randomised Study With Crossover Design in Healthy Males and Females | NCT02554734 |
| A long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Patients | A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients | JPRN-jRCT2080222710 |
| The effect of levodopa on stroke | The comparision between levodopa effect and placebo on the improvement of motor function in the patients with stroke in MCA(Middle cerebral artery),randomized.double blind study. | IRCT2014042017360N1 |
| Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence | Contingency Management Plus Levodopa/Carbidopa for Treatment of Cocaine Dependence | NCT00713583 |
| A Comparison Of The Safety And Bioavailability Of Modified-Release Formulations Of Levodopa-Carbidopa In Subjects With Parkinson’s Disease | A Comparison Of The Safety And Bioavailability Of Modified-Release Formulations Of Levodopa-Carbidopa In Subjects With Parkinson’s Disease | EUCTR2007-005033-11-DE |
| Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease | Evaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA Trial | NCT02601586 |
| Antipsychotic Augmentation With L-Dopa | Augmentation of Antipsychotics With L-Dopa (Sinemet) | NCT01636037 |
| A clinical study investigating the efficacy, tolerability, and safety of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuations | A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO) - iNDiGO | EUCTR2016-002033-30-FR |
| Evaluation of the effect of magnesium oxide on the pharmacokinetics of levodopa/carbidopa | Evaluation of the effect of magnesium oxide on the pharmacokinetics of levodopa/carbidopa - pharmacokinetic interaction between levodopa/carbidopa and magnesium oxide | JPRN-UMIN000025222 |
| A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration | Pilot Study of L-DOPA Safety and Tolerability in Patients With AMD, and Proof of Concept That L-DOPA Improves Surrogate Biomarkers in Patients With Moderate to Advanced AMD | NCT02873351 |
| Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa | The Effect of L-Dopa on the Progression of Retinitis Pigmentosa | NCT02837640 |
| A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER) | An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication) | NCT02799381 |
| A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations | A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations | NCT02782481 |
| Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide | Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide (Madopar® HBS 125): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy Volunteers | NCT02778594 |
| - | A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's Disease (BeyoND) | EUCTR2015-005814-31-AT |
| Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON | Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over Trial | NCT02769793 |
| Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes | Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes - Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes | JPRN-UMIN000007896 |
| Effect of Levodopa on depression in patients with Parkinson Disease | Effect of Levodopa on depression indices in patients with Parkinson Disease | IRCT2014092119243N1 |
| Evaluation of the pain relief of prolonged-release oxycodone and of L-Dopa, versus placebo, in Parkinson's disease. | Evaluation of the analgesic effects of prolonged-release oxycodone and of L-Dopa, versus placebo, on central neuropathic pain in Parkinson's disease : OXYDOPA trial - OXYDOPA | EUCTR2015-001523-24-FR |
| Pharmacokinetic evaluation of a pulmonary administered levodopa dry powder formulation in Parkinson*s disease. | Pharmacokinetic evaluation of a pulmonary administered levodopa dry powder formulation in Parkinson*s disease. - Levodopa dry powder inhalation in patients with Parkinson*s disease. | NL-OMON42667 |
| A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson's Disease Patients with OFF episodes | A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) | EUCTR2015-005626-19-CZ |
| Levodopa Benserazide Generic Formulation Versus the Originator | Clinical and Pharmacokinetics Study to Evaluate the Therapeutic Equivalence and Bioequivalence of Levodopa Benserazide Generic Formulation (Teva Italia) Versus the Originator (Madopar®) | NCT02741947 |
| - | A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's disease | EUCTR2015-005078-39-AT |
| Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients | "Multicentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet®) or Levodopa/Benserazide 100/25 mg (Madopar®/Restex®) and With Motor Fluctuations (""Wearing-off"" Phenomenon)" | NCT01568047 |
| - | A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's disease | EUCTR2015-005078-39-DE |
| A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson’s Disease Patients with OFF episodes | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™) | EUCTR2015-005067-17-CZ |
| Levodopa and Pramipexole dministration modalities in patients affected by parkinson desease. | Levodopa Administration Modalities and Pramipexole in Parkinson's Disease (LAMP-PD study) A multicenter, randomized, four parallel groups, active-controlled, open-label study to evaluate the risk of dyskinesia in early PD. - LAMP-PD | EUCTR2010-019396-29-IT |
| Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations. | Efficacy and safety of ODM-104 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson’s disease and end-of-dose wearing-off. - COMPOC | EUCTR2015-004507-23-DE |
| A Randomized, Double-Blind, Crossover, Comparative Pharmacokinetic Trial of Deulevodopa (TEV-50939) and Levodopa, both Administered with Carbidopa in Healthy Subjects | A Randomized, Double-Blind, Crossover, Comparative Pharmacokinetic Trial of Deulevodopa (TEV-50939) and Levodopa, both Administered with Carbidopa in Healthy Subjects - TEV-50939 and Levodopa comparative study | NL-OMON42683 |
| A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma | A Phase 1 Study of the Safety and Pharmacokinetics (PK) of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma | NCT02633007 |
| Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease | Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge Test | NCT02641054 |
| A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients | Phase 3 Multicenter Randomized Double-Blind, Double-dummy, Active-Controlled Study Comparing Efficacy/Safety of Gastric-retentive, Controlled-release Accordion Pill Carbidopa/Levodopa to Immediate Release in Fluctuating Parkinson's Patients | NCT02605434 |
| Inhalation of Levodopa in Parkinson's disease | Pharmacokinetic evaluation of a pulmonary administered levodopa dry powder formulation in Parkinson’s disease. | NL-OMON25573 |
| Vicinia FABA in Parkinson disease patients | The Effect of Vicinia Faba on Clinical signs and blood level of Levodopa in Parkinson patients comparison to Oral Levodopa | IRCT2013060313570N1 |
| A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) | An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study | NCT02549092 |
| A Study of L-DOPA for Depression and Slowing in Older Adults | A Study of L-DOPA for Depression and Slowing in Older Adults | NCT02744391 |
| A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612 | A Phase 2a Multicentre Randomized Double Blind Placebo Controlled Study Followed by an Open Label Period, to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Continuous Subcutaneous ND0612 | NCT01883505 |
| Augmenting Language Therapy for Aphasia: Levodopa | Augmenting Language Therapy for Aphasia: A Randomized Double-Blind Placebo-Controlled Trial of Levodopa in Combination With Speech-Language Therapy | NCT01429077 |
| A study investigating the safety of CVT-301 in patients with Parkinson's Disease | A Randomized, Placebo-Controlled Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CVT-301 (Levodopa Inhalation Powder) in Patients with Parkinson’s Disease and Motor Response Fluctuations (“Off” Episodes) | EUCTR2012-000181-37-GB |
| Trial of L-DOPA as a Treatment to Improve Vision in Albinism | Clinical Trial to Evaluate Levodopa as Treatment to Improve Vision in Individuals With Albinism | NCT01176435 |
| Pharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors - DuoCOMT | Pharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors - DuoCOMT | EUCTR2008-003581-26-SE |
| Expectation and Response to Levodopa and Acupuncture in Parkinson's Disease | Expectation and Response to Levodopa & Acupuncture in Parkinson's Disease | NCT00692328 |
| A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease | A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease | EUCTR2009-017238-39-FR |
| Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol. | Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol. | EUCTR2009-017416-33-DE |
| Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes | A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) | NCT01777555 |
| Pharmacokinetic Study With Repeated Doses of Stalevo | Levodopa Concentration Profile After Repeated Doses of Stalevo | NCT00693862 |
| A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics | A Randomised, Double-blind, Placebo-controlled, Two-period, Two-sequence-crossover Interaction Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease | NCT01026428 |
| Levodopa Concentration Profile With Stalevo 75/125 mg | Levodopa Concentration Profile After Repeated Doses of Different Stalevo® Strengths With 3.5 Hours Dosing Frequency; an Open, Randomised, Crossover, Levodopa/Carbidopa Controlled Single Centre Study in Healthy Subjects, Two Parallel Groups | NCT01070628 |
| Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects | A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations | NCT00660387 |
| Natural History of Levodopa-Induced Dyskinesia (LID) | Determining the Natural History of Levodopa-Induced Dyskinesia (LID) | NCT01003002 |
| Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors | Pharmacokinetics of Levodopa in Patients With Parkinson's Disease Treated With Levodopa/Carbidopa Infusion With and Without Oral COMT Inhibitors | NCT00906828 |
| Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease | Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease | NCT06772220 |
| Carbidopa-levodopa in Neovascular AMD | Short Term Effects of Carbidopa-levodopa in Neovascular AMD | NCT03022318 |
| Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics | Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics | NCT00888186 |
| A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson?s disease - A study to assess the effect of safinamide on levodopa pharmacokinetics | A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson?s disease - A study to assess the effect of safinamide on levodopa pharmacokinetics | EUCTR2008-002769-30-IT |
| Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550) | Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients | NCT00845000 |
| Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome | A Dose-escalation Tolerability Study of Levodopa/Carbidopa in Angelman Syndrome | NCT00829439 |
| Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease | Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's | NCT00096720 |
| Effect of Levodopa on Human Multifocal Electroretinogram | Effect of Levodopa on Human Multifocal Electroretinogram | NCT00812760 |
| Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia | A Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia in 8 to 17 Year Olds | NCT00789672 |
| Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease | Effect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's Disease | NCT00914134 |
| Brain activation by addition of L-Dopa to normal antipsychotic treatment in patients with schizophrenia | Selective D1 activation by addition of L-Dopa to antipsychotic treatment in patients with schizophrenia - ALOHA | EUCTR2010-019897-33-NL |
| Levodopa for the Treatment of Residual Amblyopia | A Randomized Trial of Levodopa as Treatment for Residual Amblyopia (ATS 17) | NCT01190813 |
| EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I | EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I | EUCTR2010-021860-13-HU |
| Treatment in advanced Parkinson*s disease: continuous intrajejunal levodopa infusion versus deep brain stimulation; a feasibility study | Treatment in advanced Parkinson*s disease: continuous intrajejunal levodopa infusion versus deep brain stimulation; a feasibility study - INVEST (INfusion VErsus STimulation) feasibility study | NL-OMON39084 |
| Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics | Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics of a Single-dose of Immediate Release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects | NCT02169414 |
| Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide | Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects | NCT01533116 |
| Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic | A Double-blind, Randomised, Placebo- and Active-controlled Multiple-dose Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetics Following a Levodopa/Carbidopa 100/25 mg Single-dose in Healthy Subjects | NCT01519284 |
| Comparative study of therapeutic effects of Gabapentin versus Levodopa-c on Restless legs syndrome in hemodialysis patientes | Comparative study of therapeutic effects of Gabapentin versus Levodopa-c on Restless legs syndrome in hemodialysis patientes | IRCT201112078323N1 |
| Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa | The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy | NCT01683253 |
| Levodopa in early Parkinson?s disease | Levodopa in EArly Parkinson?s disease: a prospective, randomized, double-blind, placebo-controlled, delayed start trial | ISRCTN30518857 |
| A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPONSE, AND ERYTHROCYTE SOLUBLE CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN PARKINSON'S DISEASE PATIENTS CONCOMITANTLY TREATED WITH LEVODOPA/DOPA-DECARBOXYLASE INHIBITOR | A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPONSE, AND ERYTHROCYTE SOLUBLE CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN PARKINSON'S DISEASE PATIENTS CONCOMITANTLY TREATED WITH LEVODOPA/DOPA-DECARBOXYLASE INHIBITOR | EUCTR2008-003869-72-PT |
| A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease | A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease | NCT01484990 |
| Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers | Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers: A Single- Dose Randomized- Sequence, Open -Label Crossover Study | NCT01327261 |
| Levodopa in early Parkinson*s disease;LEAP-5Y-study: Follow-up of the Levodopa in early Parkinson's disease study | Levodopa in early Parkinson*s disease;LEAP-5Y-study: Follow-up of the Levodopa in early Parkinson's disease study - LEAP-study;LEAP-5Y-study: Acroniem follow-up trial: LEAP-5Y-study | NL-OMON55477 |
| Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off | A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event-Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease and End-of-Dose Wearing Off | NCT00601978 |
| A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentials (ERPs) in Patients with Idiopathic Parkinson’s Disease and End-of-Dose Wearing Off. | A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentials (ERPs) in Patients with Idiopathic Parkinson’s Disease and End-of-Dose Wearing Off. | EUCTR2007-003134-42-DE |
| Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off | A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off | NCT01283594 |
| Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol) | Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol) | NCT00634556 |
| Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off | An 8-week, Prospective, Randomized, Double-blind, Double-dummy, Active-controlled, Multi-center Comparison Study of the Effects of Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off | NCT00642356 |
| Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy | Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy | NCT00957918 |
| A Trial of Levodopa in Angelman Syndrome | A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome | NCT01281475 |
| A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients | A Phase I/IIa, Single Dose, Single-centre, Randomized, Crossover, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients | NCT01725802 |
| Duration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multicentre, single dose study in patients with Parkinson’s disease and wearing-off symptoms - PARTEST | Duration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multicentre, single dose study in patients with Parkinson’s disease and wearing-off symptoms - PARTEST | EUCTR2010-022915-21-FI |
| A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease | An Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects With Advanced Parkinson's Disease | NCT01736176 |
| Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. | "Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With ""Wearing-off"" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Study." | NCT01227655 |
| Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial. | Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial. | EUCTR2010-022363-35-DE |
| CLINICAL AND PHARMACOLOGICAL STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®) | CLINICAL AND PHARMACOKINETICS STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®) | EUCTR2012-001245-40-IT |
| Dose Ranging Study of Carbidopa-levodopa | Proof of Concept and Dose Ranging Study of Carbidopa-levodopa in Neovascular AMD | NCT03023059 |
| Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine | A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Study of Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine | NCT04173832 |
| "Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With ""Wearingoff"" Phenomenon" | "A Multicentre, Double-blind, Randomised, Active- and Placebo-controlled Trial to Investigate the Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With ""Wearingoff"" Phenomenon Treated With Levodopa/Carbidopa or Levodopa/Benserazide" | NCT03103399 |
| Improved Language Acquisition With Levodopa | Improved Language Acquisition With Levodopa | NCT00103805 |
| A randomised, double-blind, double-dummy, two-period, cross-over study to determine the pharmacokinetics, pharmacodynamics and safety of multiple doses of V1512 effervescent tablets in Parkinson s Disease PD patients compared to standard levodopa/carbidopa Sinemet oral tablets - ND | A randomised, double-blind, double-dummy, two-period, cross-over study to determine the pharmacokinetics, pharmacodynamics and safety of multiple doses of V1512 effervescent tablets in Parkinson s Disease PD patients compared to standard levodopa/carbidopa Sinemet oral tablets - ND | EUCTR2006-004112-51-IT |
| Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease | An Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects With Advanced Parkinson's Disease and Severe Motor Fluctuations Despite Optimized Treatment With Available Parkinson's Disease Medications | NCT00335153 |
| Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects | Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects | NCT00360568 |
| Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD | Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies | NCT00660673 |
| Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers | A Randomized, Two-Way Crossover Study to Investigate the Bioavailability of a Single Oral Dose of 37.5 mg Carbidopa, 150 mg Levodopa and 200 mg Entacapone Compared to a Single Oral Combined Dose of Both 37.5 mg Carbidopa and 150 mg Levodopa and 200 mg Entacapone in Healthy Volunteers Under Fasting Conditions | NCT00415922 |
| Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers | A Randomized, Two-Way Crossover Study to Investigate the Bioavailability of a Single Oral Dose of 12.5 mg Carbidopa, 50 mg Levodopa and 200 mg Entacapone Compared to a Single Oral Combined Dose of Both 12.5 mg Carbidopa and 50 mg Levodopa and 200 mg Entacapone in Healthy Volunteers Under Fed Conditions | NCT00415831 |
| Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone Under Fasting Conditions in Healthy Volunteers | A Randomized, Two-Way Crossover Study to Investigate the Bioavailability of a Single Oral Dose of 25 mg Carbidopa, 100 mg Levodopa and 200 mg Entacapone Compared to a Single Oral Combined Dose of Both 25 mg Carbidopa and 100 mg Levodopa and 200 mg Entacapone in Healthy Volunteers Under Fasting Conditions | NCT00415844 |
| Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers | A Randomized, Two-Way Crossover Study to Investigate the Bioavailability of a Single Oral Dose of 12.5 mg Carbidopa, 50 mg Levodopa and 200 mg Entacapone Compared to a Single Oral Combined Dose of Both 12.5 mg Carbidopa and 50 mg Levodopa and 200 mg Entacapone in Healthy Volunteers Under Fasting Conditions | NCT00415740 |
| Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy | Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy | NCT00432393 |
| Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy | A Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy | NCT00099268 |
| Modulación dopaminérgica de las funciones cognitivas y afectivas por el tratamiento con diferentes métodos de estimulación dopaminérgica en la enfermedad de Parkinson . Implicaciones para el tratamiento con levodopa. | Modulación dopaminérgica de las funciones cognitivas y afectivas por el tratamiento con diferentes métodos de estimulación dopaminérgica en la enfermedad de Parkinson . Implicaciones para el tratamiento con levodopa. | EUCTR2006-002408-32-ES |
| A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects | An Open Label, Multiple-Dose Study ot Determine the Plasma Levodopa Profiles of Sinemet® CR (Carbidopa/Levodopa) at 4 Daily Dose Levels in Healthy Subjects | NCT00460954 |
| Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1) | Quantification of Levodopa Induced Dyskinesia in Parkinson Disease: Developing Objective Measures of Levodopa Induced Dyskinesia (Study One) | NCT00467597 |
| Safety and tolerability trial of an eye drop treatment for short sightedness (myopia) | Phase 1 safety and tolerability trial of levodopa eye drops for the treatment of short sightedness (myopia) | ACTRN12620001259932 |
| A Study of MK0657 in Parkinson's Disease Patients (0657-006) | A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate Effectiveness of Single-Dose MK0657 in Combination With Levodopa on Motor Symptoms and Dyskinesias in Patients With Parkinson's Disease | NCT00505843 |
| Reconnaissance des expressions émotionnelles du visage et classification émotionnelle de mots dans la maladie de Parkinson : Influence de la stimulation cérébrale profonde du noyau sous thalamique et de la L-Dopa. - MPI-Emotions | Reconnaissance des expressions émotionnelles du visage et classification émotionnelle de mots dans la maladie de Parkinson : Influence de la stimulation cérébrale profonde du noyau sous thalamique et de la L-Dopa. - MPI-Emotions | EUCTR2007-002800-16-FR |
| Effects of single doses of Stalevo 200 and levodopa/carbidopa 200/50 mg on striatal 11C-raclopride binding potential in Parkinson’s disease patients with wearing-off symptoms. An open, randomised, active-controlled, two-period crossover study. | Effects of single doses of Stalevo 200 and levodopa/carbidopa 200/50 mg on striatal 11C-raclopride binding potential in Parkinson’s disease patients with wearing-off symptoms. An open, randomised, active-controlled, two-period crossover study. | EUCTR2007-002496-14-FI |
| Different dyskinesias in Parkinson's disease and their relation to levodopa pharmacokinetics - The dyskinesia study | Different dyskinesias in Parkinson's disease and their relation to levodopa pharmacokinetics - The dyskinesia study | EUCTR2007-004985-41-SE |
| The role of striatal serotonergic terminals in L-dopa induced-dyskinesia in Parkinson's disease patients: An in vivo Positron emission tomography (PET) study | The role of striatal serotonergic terminals in L-dopa induced-dyskinesia in Parkinson's disease patients: a proof of concept study | ISRCTN03683971 |
| Does levodopa/carbidopa, a common Parkinson's Disease drug, affect stomach emptying, blood pressure and heart rate? | Acute effects of dopaminergic therapy with levodopa/carbidopa on the gastric emptying, blood pressure and superior mesenteric artery blood flow responses to oral glucose in patients with mild to moderate Parkinson’s disease. | ACTRN12624001010583 |
| Dose-finding Pharmacokinetic Study in Healthy Males | A Dose-finding Study for Levodopa, Carbidopa and ODM-104 Test Formulations After Repeated Administration in Healthy Males | NCT03055936 |
| Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study | COMPARISON OF ORALLY DISSOLVING LEVODOPA (PARCOPA®) TO CONVENTIONAL ORAL LEVODOPA: A SINGLE DOSE, DOUBLE-BLIND, PLACEBO CONTROLLED, CROSS-OVER TRIAL | NCT00590122 |
| Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease | A Prospective, Multi-center, Randomized, Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off | NCT00219284 |
| Timing of Levodopa Treatment in Parkinson's Disease | Earlier Versus Later L-Dopa in Parkinson's Disease | NCT00004733 |
| Levetiracetam Treatment of L-dopa Induced Dyskinesias | Levetiracetam Treatment of L-dopa Induced Dyskinesias | NCT00076674 |
| A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PD | A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PD | EUCTR2004-000185-12-FI |
| A Study on Changes in Copeptin and Blood Metabolites in Healthy Adults Before and After Water Loading, Oral Levodopa Intake, and Water Deprivation | A Study on Changes in Copeptin and Blood Metabolites in Healthy Adults Before and After Water Loading, Oral Levodopa Intake, and Water Deprivation | ChiCTR2500103341 |
| Feasibility Study Assessing the Effect of Carbidopa/levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. | A Monocentric, Randomized, Double-blind Study to Assess the Feasibility of Conducting a Full-scale Randomized Controlled Trial (RCT) Assessing the Effect of Carbidopa/levodopa Ratio on Orthostatic Hypotension (OH) in Multiple System Atrophy - Parkinsonian Type (MSA-P) and Parkinson Disease (PD) Patients (CARBIDOH) | NCT06831500 |
| A randomized, double blind, placebo-controlled study to investigate the effect of E2007 on pharmacodynamic responses to levodopa among patients with Parkinson's disease who experience dyskinesia and motor fluctuations. - E2007-E044-213 | A randomized, double blind, placebo-controlled study to investigate the effect of E2007 on pharmacodynamic responses to levodopa among patients with Parkinson's disease who experience dyskinesia and motor fluctuations. - E2007-E044-213 | EUCTR2006-005714-12-IT |
| A Study to evaluate the blood levels of Carbidopa 61.25 mg and Levodopa 245 mg Capsules as a test compared to the Reference RYTARY (Carbidopa and Levodopa) Capsules 61.25 mg/ 245 mg (R) in normal healthy subjects under fed and fasting condition. | An open label, randomized, balanced, two treatment, two sequence, two period, cross-over, single-dose, oral bioequivalence study of Carbidopa 61.25 mg and Levodopa 245 mg Extended Release Capsules (T) Manufactured by ScieGen Pharmaceuticals, Inc 89 Arkay Drive, Hauppauge, New York- 11788, United States with RYTARY® (Carbidopa and Levodopa) Extended Release Capsules 61.25 mg/ 245 mg (R) Manufactured by Bora Pharmaceutical Laboratories Inc. Jhunan, Taiwan and Distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 in normal healthy, adult male and female subjects under fed and fasting condition. - NIL | CTRI/2025/01/079338 |
| Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médical | Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médical | EUCTR2010-020769-25-FR |
| Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease | Impact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study) | NCT01538329 |
| Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease | A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease | NCT00129181 |
| A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa | A 39 Week Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Effect of Fixed Dose Carbidopa/Levodopa/Entacapone 100 mg t.i.d. vs. Immediate Release Carbidopa/Levodopa 25/100 mg (t.i.d.) in Parkinson's Disease Patients Requiring Levodopa | NCT00134966 |
| Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States | Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. | NCT00143026 |
| A long-term health economics study of intraduodenal levodopa (Duodopa®) in routine care for patients with advanced idiopathic Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia. - DAPHNE | A long-term health economics study of intraduodenal levodopa (Duodopa®) in routine care for patients with advanced idiopathic Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia. - DAPHNE | EUCTR2005-002654-21-SE |
| Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome | Swiss Restless Legs Syndrome Trial (SRLS) A Double-blind, Randomised, Crossover Trial Investigating the Efficacy and Safety of the Dopamine Agonist Pramipexole (Sifrol®, 0.25-0.75 mg Per Day) Versus Levodopa / Benserazide (Madopar® DR, 125-375 mg Per Day) in Patients With Restless Legs Syndrome | NCT00144209 |
| Efficiency and tolerability of L-Dopa in patients with Hereditary Spastic Paraplegia (HSP) | Efficiency and tolerability of L-Dopa in patients with Hereditary Spastic Paraplegia (HSP) | EUCTR2004-004509-11-DE |
| Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease. | A Double-Blind, Randomized, Comparative Study of Cabaser and Sinemet CR For The Treatment Of Nocturnal Disability In Levodopa -Treated Parkinson's Disease Patients. | NCT00174239 |
| Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence | Behavioral Strategies to Maximize the Efficacy of Pharmacotherapy for Cocaine Dependence: Relapse Prevention With Contingency Management Procedures | NCT00218075 |
| A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step | A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step | EUCTR2005-001032-72-PT |
| Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP | Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP | EUCTR2004-005234-39-GB |
| Effects on the pharmacokinetics of L-DOPA formulation by Proton pump inhibitors in patients with Parkinson's disease | Effects on the pharmacokinetics of L-DOPA formulation by Proton pump inhibitors in patients with Parkinson's disease - Effects on the pharmacokinetics of L-DOPA formulation by Proton pump inhibitors in patients with Parkinson's disease | JPRN-UMIN000022529 |
| Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit | Continuous Delivery of Levodopa/Carbidopa (Duodopa) in Patients With Advanced Idiopathic Parkinsons Disease - a Health Economic Evaluation | NCT00272688 |
| Estudio multicéntrico, doble ciego, aleatorizado y de tres meses de seguimiento para evaluar la eficacia de levodopa/carbidopa/entacapona frente a levodopa/carbidopa en pacientes con enfermedad de Parkinson y “wearing-off”A 3-months, multicenter, double-blind, randomized study to evaluate the efficacy of levodopa/carbidopa/entacapone vs. levodopa/carbidopa in Parkinson's disease patients with 'wearing-off' - DERBI | Estudio multicéntrico, doble ciego, aleatorizado y de tres meses de seguimiento para evaluar la eficacia de levodopa/carbidopa/entacapona frente a levodopa/carbidopa en pacientes con enfermedad de Parkinson y “wearing-off”A 3-months, multicenter, double-blind, randomized study to evaluate the efficacy of levodopa/carbidopa/entacapone vs. levodopa/carbidopa in Parkinson's disease patients with 'wearing-off' - DERBI | EUCTR2006-000680-28-ES |
| Investigating the use of nicotine for treating complications of levodopa therapy in Parkinsons disease | Investigating the role of nicotinic neuromodulation in levodopa-induced dyskinesias â?? a multimodal study. | CTRI/2020/12/029965 |
| Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) | Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) | NCT01397422 |
| Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients - SENSE | Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients - SENSE | EUCTR2006-001755-36-SE |
| A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A | A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A | EUCTR2004-001485-41-AT |
| Effects of L-DOPA on memory consolidation in older adults | Effects of L-DOPA on memory consolidation in older adults - ELISA | DRKS00026161 |
| L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease | A Randomized, Single-blind Trial on the Efficacy and Safety of L-dopa Monotherapy Versus Dopamine Agonists Monotherapy After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease | NCT02347059 |
| Effect of Folic Acid in Levodopa Treated Parkinson's Disease Patients | Effect of Folic Acid on Motor Aspects of Daily Living and Oxidative Stress in Levodopa Treated Parkinson's Disease Patients: A Randomized, Double-Blind, Placebo Controlled Trial | NCT05959044 |
| Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects | A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations | NCT00357994 |
| A randomised, double-blind, placebo-controlled, dose escalation study of single and multiple oral dose administration of BIIB014 in subjects with moderate to late stage parkinson's disease who are also receiving treatment with levodopa | | ISRCTN12870393 |
| Effect of Vitamin B12, Folate, and Entacapone in Levodopa-induced hyperhomocysteinemia | Effect of Vitamin B12, Folate, and Entacapone in Levodopa-induced hyperhomocysteinemia | TCTR20181221001 |
| Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off | A 3-month, Multi-center, Double-blind, Randomized Study to Evaluate the Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Impairment of Activities of Daily Living and Early Wearing-off With Levodopa | NCT00391898 |
| A 16 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by Levodopa | A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias | EUCTR2014-001131-36-ES |
| A 26 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by Levodopa | A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias | EUCTR2014-001132-10-ES |
| Open-Label Safety Study of ADS-5102 in PD Patients With LID | Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID) | NCT02202551 |
| Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID. | A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias | NCT02153645 |
| Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID | A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias | NCT02153632 |
| ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) | Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study) | NCT02136914 |
| The influence of white noise and dopamine on language learning in healthy young adults. | The influence of white noise and levodopa on language learning in healthy young adults. | ACTRN12620000809932 |
| In-vivo Bioequivalence Study of Levodopa/Benserazide 200/50mg FC Tablet of The Test Drug (MINOPAR 250 mg) manufactured by Teb mofid nikan | In-vivo Bioequivalence Study of Levodopa/Benserazide 200/50mg FC Tablet of The Test Drug (MINOPAR 250 mg) manufactured by Teb mofid nikan in Compared with The Reference Drug (MADOPAR 250 mg FC Tablet. Roche , Switzerland) | IRCT20200105046010N125 |
| Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease | An Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Relationship Study of L-Dopa/Carbidopa in a Novel Release Formulation in Parkinson's Disease Patients | NCT00558337 |
| In vivo Bioequivalence study of Levodopa/benserazide tablets | In vivo fasted-state bioequivalence study of Levodopa/Benserazide (250/50) tablets manufactured by Bakhtar Bioshimi Co. compared to innovator product | IRCT20220211053992N34 |
| Comparison of gastrointestinal function before and after levodopa-carbidopa continuous infusion gel (LCIG) therapy for patients with Parkinson's disease | Comparison of gastrointestinal function before and after levodopa-carbidopa continuous infusion gel (LCIG) therapy for patients with Parkinson's disease - Comparison of gastrointestinal function before and after LCIG therapy for Parkinson's disease | JPRN-UMIN000040889 |
| An open-label study of combination therapy of CNSA-001 with levodopa in patients with Parkinson's Disease for the treatment of motor and non-motor symptoms of Parkinson's Disease. | A Phase 2a Open-Label Study of CNSA-001 in Patients with Parkinson’s Disease | ACTRN12620000671965 |
| Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease | A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients | NCT04380142 |
| Validation of finger tapping in PD patients | Randomized, double-blind, placebo-controlled crossover study to validate finger tapping tasks for the quantification of levodopa/carbidopa effects in Parkinson’s Disease patients. | EUCTR2020-000686-16-NL |
| Randomized, double-blind, placebo-controlled crossover study to validate finger tapping tasks for the quantification of levodopa/carbidopa effects in Parkinson*s Disease patients. | Randomized, double-blind, placebo-controlled crossover study to validate finger tapping tasks for the quantification of levodopa/carbidopa effects in Parkinson*s Disease patients. - Validation of finger tapping in PD patients | NL-OMON49757 |
| A randomized, double-blind, placebo-controlled pre-trial study of SYMBLYOPIA (Levodopa Tablets) for the treatment of amblyopia in children | A randomized, double-blind, placebo-controlled pre-trial study of SYMBLYOPIA (Levodopa Tablets) for the treatment of amblyopia in children | ChiCTR2000030023 |
| The Efficacy of Levodopa/Carbidopa/Entacapone in Moderate to Advanced Parkinson's Disease | The Efficacy of Levodopa/Carbidopa/Entacapone in Moderate to Advanced Parkinson's Disease | ChiCTR2400091631 |
| 3D gait analysis and L-DOPA in Dravet syndrome. | 3D gait analysis and effectiveness of L-DOPA on pathological gait in Dravet syndrome. | JPRN-jRCTs041190116 |
| Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity | Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity | NCT04082715 |
| Intervention study for the effect of Istradefylline on adjustment of Levodopa in Parkinson's Disease - Istra adjust PD | JPRN-jRCTs031180248 |
| Effectiveness of treatment in Parkinsons disease | Comparison of effectiveness of trihexyphenidyl and levodopa on motor symptoms in Parkinsonâ??s disease | CTRI/2019/03/017955 |
| Enhancement of Stroke Rehabilitation With Levodopa | Enhancement of Stroke Rehabilitation With Levodopa (ESTREL): a Randomized Placebo-controlled Trial | NCT03735901 |
| A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor Fluctuations | A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations | NCT03670953 |
| â??A Study to Evaluate the Efficacy of Shirobasti(Pulling of medicated oil) and Nasya(medicinal nasal drops) With and Without Medicine (Levodopa) in the Management of Kampavata (Parkinsonâ??s Disease). | â??An Open Clinical Study to Evaluate the Efficacy of Shirobasti and Nasya With and Without Levodopa in the Management of Kampavata w.s.r. to Parkinsonâ??s Disease (PD). | CTRI/2018/08/015533 |
| WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects | AN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL AND ORAL DOSE, CROSSOVER PHARMACOKINETICS STUDY OF WD-1603 EXTENDED-RELEASE CARBIDOPA/LEVODOPA TABLETS 25/100MG IN NORMAL, HEALTHY, ADULT HUMAN SUBJECTS UNDER FASTING AND FED CONDITIONS | NCT04513340 |
| To study the effect of adding a medicine (called levodopa) to existing treatment in patients with schizophrenia | Augmentation of antipsychotics with levodopa - fMRI study to examine neurobiological effects of L-dopa in Schizophrenia | CTRI/2018/08/015367 |
| Enhancing Motor Learning with a Single Dose of Levodopa | Enhancing Motor Learning with a Single Dose of Levodopa - Improving motor learning II | NL-OMON46724 |
| Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients | An Open Label Phase 2 Study to Assess the Pharmacokinetics of the Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Patients With Parkinson's Disease | NCT03576638 |
| Effects of levodopa on masticatory and oral sensory function in Parkinson’s Disease | Oral health and chewing function in patients with Parkinson’s Disease | RBR-7k4ttg |
| A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa. | A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease | NCT03496870 |
| - | A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension | EUCTR2017-002780-17-FR |
| Carbidopa-Levodopa in Dry AMD With Geographic Atrophy | Carbidopa-Levodopa in Dry Age Related Macular Degeneration With Geographic Atrophy | NCT03451500 |
| Effectiveness of inhaled levodopa in Parkinson's disease | Therapeutic effects of an inhaled levodopa dry powder formulation on the recovery from off periods in patients with Parkinson's disease | NL-OMON22984 |
| Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the blood levels of Levodopa Administered as ND0612 via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Duodopa. | A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension | EUCTR2017-002780-17-ES |
| The effect of inhaled levodopa on the recovery from off periods in patients with Parkinson's disease | Therapeutic effects of an inhaled levodopa dry powder formulation on the recovery from off periods in patients with Parkinson's disease - Effectiveness of inhaled levodopa in Parkinson's disease | EUCTR2017-004006-18-NL |
| Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission | L-Dopa Modulated Striatal Functional Connectivity in Schizotypal Adults: a Randomized Double-blind Placebo-controlled Study | NCT03333369 |
| Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome | Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome | NCT03235037 |
| Extension, Carbidopa-levodopa in Neovascular AMD | Extension of Protocol 002, Carbidopa-levodopa in Neovascular Extension of Protocol 002, Carbidopa-levodopa in Neovascular AMD | NCT03197493 |
| Levodopa and chlorpromazine combination therapy for treatment of primary dystonia | Levodopa and chlorpromazine combination therapy for treatment of primary dystonia - Levodopa and chlorpromazine combination therapy for treatment of primary dystonia | JPRN-UMIN000027430 |
| Pharmacokinetic of Levodopa Study in Healthy Males | Pharmacokinetics of Levodopa After Repeated Doses of Different Pellet Formulations; An Open, Randomized Study With Crossover Design in Healthy Male Subjects | NCT03140956 |
| Non-inferiority study of zonisamide versus levodopa preparations in DLB parkinsonism | Efficacy of adjunctive therapy of zonisamide versus increased dose of levodopa for motor symptom in DLB parkinsonism : a randomized, controlled, non-inferiority study. - DUEL | JPRN-jRCTs051200054 |
| Vision Response to Dopamine Replacement | Interventional Study of Levodopa Replacement on Retinal Function in Oculocutaneous Albinism | NCT01663935 |
| Study of bioequivalence of Levodopa/Carbidopa/Entecapone tablet 200/50/200mg Fanda Pharma (Staparkin 200/50/200mg) and foreign samples on 24 healthy Iranian volunteers. | In- Vivo Bioequivalence study of Levodopa/Carbidopa/Entecapone tablet 200/50/200mg Fanda Pharma (Staparkin 200/50/200mg) with brand drugs (Stalevo 200/50/200mg Novartis, Germany) in Iranian healthy volunteers. | IRCT20200105046010N9 |
| Comparison of Clinical Response, Pharmacokinetics and Systems Pharmacology Between Dispersible Form of Levodopa and Mucuna pruriens Powder in Parkinson s disease | Comparison of Clinical Response, Pharmacokinetics and Systems Pharmacology Between Dispersible Form of Levodopa and Mucuna pruriens Powder in Parkinson s disease | TCTR20220607005 |
| Comparative in vivo evaluation of 2 Levodopa/Benserazide 200/50 mg Tablet formulations. | Comparative bioequivalence study of Levodopa/Benserazide 200/50 mg tablet of Cosar pharmaceutical Co. and Madopar 250 mg tablet of Roche as reference in 24 healthy male under fasting. | IRCT20180620040164N30 |
| Open Label Study For Ayurvedic Treatment On Parkinsons Disease. | Study Open Label Pilot study Of An Ayurvedic Treatment Regime On Levodopa Non-responding Parkinsonism (kampavata). | CTRI/2020/09/027705 |
| Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease | Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease With and Without Orthostatic Hypotension: a Cross-over Study | NCT05487300 |
| Genetic variation-environment interaction and levodopa sensitivity related to pathological myopia: A before-after control study of levodopa in young children with myopia and amblyopia | Genetic variation-environment interaction and levodopa sensitivity related to pathological myopia: A before-after control study of levodopa in young children with myopia and amblyopia | ChiCTR2200064571 |
| Evaluation of administration of a single dose of Levodopa through a novel oral and maxillofacial route in Parkinsons patients | EVALUATION OF A NOVEL ORAL AND MAXILLOFACIAL ROUTE OF DRUG ADMINISTRATION IN PARKINSONâ??S PATIENTS USING A DRUG DELIVERY SYSTEM. | CTRI/2023/04/051539 |
| A Pharmacodynamics and Safety Study of DSP-9632P | A Pharmacodynamics and Safety Study of DSP-9632P in Patients with Levodopa-Induced Dyskinesia in Parkinson's Disease | JPRN-jRCT2031220051 |
| The Correlation of Reduction of Levodopa and Non-motor Symptoms of Parkinson's Disease After Deep Brain Stimulation | The Correlation of Reduction of Levodopa and Non-motor Symptoms of Parkinson's Disease After Deep Brain Stimulation | NCT05901350 |
| Comparison of Dopamin Level in Idiopathic Parkinson's Patients | Comparison of Blood Dopamine Levels in Idiopathic Parkinson's Patients Receiving Levodopa Carbidopa Entacapone or Levodopa Benserazide | NCT06115538 |
| Effectiveness and Pharmacokinetics Parameters of WD- 1905 Tablets with SINEMET® (carbidopa and levodopa) Tablets in Parkinsons Disease (PD) Subjects with Morning Akinesia. | An Open-Label, Multicenter, Randomized, Two-Treatment, Two-Periods, Two-Sequence, Comparative pharmacokinetic and Effectiveness Study of WD- 1905 Tablets with SINEMET® (carbidopa and levodopa) Tablets in Parkinsons Disease (PD) Subjects with Morning Akinesia. - NIL | CTRI/2023/12/060430 |
| Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in the Postprandial State in Healthy Chinese Subjects | Single-Center, Open, Randomized, Single-Dose, Completely Repeated Crossover Bioequivalence Study to Evaluate the Effects of the Test/Reference Preparation, Entacapone,Levodopa and Carbidopa Tablets (II) in the Postprandial State in Healthy Adult Subjects | NCT06180720 |
| Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease | Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease | NCT06236230 |
| Efficacy and safety of levodopa in dystonia due to neurological Wilson disease, an open labeled placebo controlled randomized controlled trial | Efficacy and safety of levodopa in dystonia due to neurological Wilson disease, an open labeled placebo controlled randomized controlled trial | CTRI/2024/02/062899 |
| The effectiveness of Lavandula stoechas in Parkinson's disease | The efficacy of Lavandula stoechas product on motor symptoms of patients with Parkinson's disease treated with levodopa : A double-blind clinical trial | IRCT20230505058093N1 |
| Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects | Single-Center, Open, Randomized, Single-Dose, Completely Repeated Crossover Bioequivalence Study to Evaluate the Effects of the Test/Reference Preparation, Entacapone,Levodopa and Carbidopa Tablets (II) in Healthy Adult Subjects | NCT05976737 |
| Bioavailability of Levodopa 250 mg and Carbidopa 25 mg With Regards to Reference Product | Bioavailability of a Formulation of Oseltamivir Phosphate 75 mg Tablets With Regards to the Reference Product | NCT05250141 |
| Can the antibiotic Doxycycline help control the complications (dyskinesias) of levodopa treatment in patients with Parkinson's Disease? | Pilot study to verify the safety and efficacy of Doxycycline in the treatment of levodopa-induced dyskinesias in patients with Parkinson's disease | RBR-1047fwbf |
| Levodopa effect on recovery of Stroke | Investigation of Levodopa effect on recovery of Stroke patients | IRCT20211018052808N1 |
| Pharmacology of levodopa/carbidopa versus levodopa/benserazide in patients with parkinson's disease | Pharmacology of levodopa/carbidopa versus levodopa/benserazide in patients with parkinson's disease | ChiCTR2000039201 |
| Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing | Combination Treatment With L-DOPA and Exercise for Mood and Mobility Problems in Late-Life | NCT04650217 |
| A multicenter, parallel-group, rater-blinded, randomized clinical studyinvestigating the efficacy, safety, tolerability and pharmacokinetics of2 dosing regimens of ND0612H, a solution of levodopa/carbidopadelivered via a pump system as a continuous subcutaneous infusion insubjects with advanced Parkinson's disease - NA | EUCTR2015-005078-39-IT |
| Investigating the DopaFuse® Delivery System in Parkinson’s Disease Patients. Assessing safety, effectiveness, how well it is tolerated, and how the drug is processed by the body. | Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa via the DopaFuse Delivery System in Parkinson’s Disease Patients - Study of Continuous Oral Levodopa: SCOL | EUCTR2020-003372-41-ES |
| Levodopa Response and Gut Microbiome in Patients With Parkinson's Disease | Levodopa Response and Gut Microbiome in Patients With Parkinson's Disease | NCT04956939 |
| Clinical study in early PD patients to investigate the effect of Opicapone 50mg or Levodopa 100 mg in the treatment of motor fluctuations. | A randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study to evaluate the add-on effect of opicapone 50 mg or levodopa 100 mg as first strategy for the treatment of wearing-off in patients with Parkinson’s Disease. - ADOPTION: eArly levoDopa with Opicapone in Parkinson’s paTients wIth motOr fluctuatioNs | EUCTR2020-002754-24-DE |
| In vivo Bioequivalence study of Levodopa/benserazide tablets | In vivo fasted-state bioequivalence study of Levodopa/Benserazide (250/50) tablets manufactured by Sobhan Pharmaceutical Co. compared to innovator product | IRCT20220211053992N32 |
| A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease | A Phase II Randomized, Parallel, Double-blind, Placebo-controlled, Multi-center Clinical Trial of the Efficacy and Safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease | NCT05036473 |
| Investigating the DopaFuse® Delivery System in Parkinson's Disease Patients. Assessing safety, effectiveness, how well it is tolerated, and how the drug is processed by the body. | Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa via the DopaFuse® Delivery System in Parkinson’s Disease Patients - Study of Continuous Oral Levodopa: SCOL | EUCTR2020-003372-41-IT |
| bioequivalence study of Levodopa 200 mg + Benserazide 50 mg tablets in 24 healthy male under fasting conditions | Randomized, single-dose, crossover comparative bioequivalence study of Levodopa 200 mg + Benserazide 50 mg tablets of Abian Pharmed Co. and ROCHE in 24 healthy male under fasting conditions | IRCT20180620040164N6 |
| Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions | An Open-label, Balanced, Randomized, Five-treatment, Five-period, Five-sequence, Multiple Oral Dose, Crossover Comparative Bioavailability Study of Different Strengths of Carbidopa/Levodopa Extended-release Tablets With Carbidopa and Levodopa Tablets in Normal, Healthy Adult Human Subjects Under Fasting and Fed Conditions | NCT05128175 |
| A NON-RANDOMIZED, OPEN-LABEL, CROSS-OVER, DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECTS OF BIA 28-6156 AT STEADY-STATE ON THE PHARMACOKINETICS OF LEVODOPA/CARBIDOPA AND LEVODOPA/BENSERAZIDE IN HEALTHY SUBJECTS. | A NON-RANDOMIZED, OPEN-LABEL, CROSS-OVER, DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECTS OF BIA 28-6156 AT STEADY-STATE ON THE PHARMACOKINETICS OF LEVODOPA/CARBIDOPA AND LEVODOPA/BENSERAZIDE IN HEALTHY SUBJECTS. - BIA 28-6156 & L-Dopa plus Carbidopa or Benserazide DDI in healthy subjects | NL-OMON50655 |
